The Experts below are selected from a list of 978 Experts worldwide ranked by ideXlab platform
Jeanchristophe Thalabard - One of the best experts on this subject based on the ideXlab platform.
-
Short Communication Cyclical Mastalgia and Breast Cancer Risk: Results of A French Cohort Study
2016Co-Authors: Monique G. Lê, Regine Sitruk-ware, Jeanchristophe ThalabardAbstract:Cyclical Mastalgia is a common complaint, with a poten-tially important relationship to breast cancer risk. In the last decade, case-control studies have reported that cyclical Mastalgia could be considered as an independent risk fac-tor for breast cancer. The subjectivity of a retrospectively collected symptom questioned the validity of this finding. We have examined the association between cyclical mastal-gia and breast cancer risk in the French cohort study of women with benign breast disease diagnosed in two breast clinics between 1976 and 1979 and followed-up until 1997. The present study was restricted to the women free of any hormonal treatment (n = 247). The mean follow-up was 16 F 5 years, and a total of 22 breast cancers occurred during the follow-up. Using a Cox model with duration of cyclical Mastalgia as a time-varying variable, the adjusted relative risk of breast cancer increased with the duration of cyclical Mastalgia (P = 0.006). The corresponding relative risk for 37 months of cyclical Mastalgia was 5.31 (95% confidence interval, 1.92-14.72). We show here that the conclusion still holds when the symptom cyclical Mastalgia was collected prospectively in a cohort study, bringing additional evidence that cyclical Mastalgia may represent an independent and useful clinical marker of increased breast cancer risk. It might be a confounding factor when assessing the effects of hormonal treatments on breast cancer risk such as hormonal replacement therapy or ora
-
cyclical Mastalgia and breast cancer risk results of a french cohort study
Cancer Epidemiology Biomarkers & Prevention, 2006Co-Authors: Genevieve Plubureau, Regine Sitrukware, Jeanchristophe ThalabardAbstract:Cyclical Mastalgia is a common complaint, with a potentially important relationship to breast cancer risk. In the last decade, case-control studies have reported that cyclical Mastalgia could be considered as an independent risk factor for breast cancer. The subjectivity of a retrospectively collected symptom questioned the validity of this finding. We have examined the association between cyclical Mastalgia and breast cancer risk in the French cohort study of women with benign breast disease diagnosed in two breast clinics between 1976 and 1979 and followed-up until 1997. The present study was restricted to the women free of any hormonal treatment (n = 247). The mean follow-up was 16 +/- 5 years, and a total of 22 breast cancers occurred during the follow-up. Using a Cox model with duration of cyclical Mastalgia as a time-varying variable, the adjusted relative risk of breast cancer increased with the duration of cyclical Mastalgia (P = 0.006). The corresponding relative risk for 37 months of cyclical Mastalgia was 5.31 (95% confidence interval, 1.92-14.72). We show here that the conclusion still holds when the symptom cyclical Mastalgia was collected prospectively in a cohort study, bringing additional evidence that cyclical Mastalgia may represent an independent and useful clinical marker of increased breast cancer risk. It might be a confounding factor when assessing the effects of hormonal treatments on breast cancer risk such as hormonal replacement therapy or oral contraceptives.
Deborah N Ader - One of the best experts on this subject based on the ideXlab platform.
-
cyclical Mastalgia premenstrual syndrome or recurrent pain disorder
Journal of Psychosomatic Obstetrics & Gynecology, 1999Co-Authors: Deborah N Ader, C D Shriver, M W BrowneAbstract:Approximately 8-10% of premenopausal women experience moderate to severe perimenstrual breast pain or cyclical Mastalgia, monthly. This Mastalgia can occur regularly for years until menopause, can interfere with usual activities, and is associated with elevated utilization of mammography among young women. Although Mastalgia is a well documented symptom in premenstrual syndrome (PMS), it is unknown whether PMS is necessarily present in women with cyclical Mastalgia. The present study prospectively examined Mastalgia and its relationship to PMS. Thirty-two premenopausal women reporting recent Mastalgia completed breast pain and menstrual symptom scales daily for 3-6 months. Eleven women (34.4%) met criteria for clinically significant cyclical Mastalgia, reporting an average of 10.2 days of moderate-severe Mastalgia monthly. Five women (15.6%) met criteria for PMS. Mastalgia was not significantly associated with PMS: 82% of women with clinical cyclical Mastalgia did not have PMS. Cyclical Mastalgia, although by definition associated with the menstrual cycle, is not simply premenstrual syndrome, and merits further investigation as a recurrent pain disorder whose presentation, etiology, and effective treatment are likely to differ from those of PMS.
-
clinical evaluation of Mastalgia
Archives of Surgery, 1998Co-Authors: Houman Tavafmotamen, Deborah N Ader, Matrice W Browne, Craig D ShriverAbstract:Objective To describe an accurate and reproducible method to quantify a patient's subjective experience of breast pain. Design Prospective diary study. Setting Military tertiary care hospital. Patients Thirty female military health care beneficiaries from the Walter Reed Army Medical Center, Washington, DC, gynecology and general surgery clinics. Main Outcome Measures Daily Mastalgia was recorded using a visual analog scale and menstrual symptoms were measured using a daily questionnaire. These measures were correlated with results of a screening questionnaire completed prior to study entry. Results Patients identified as having cyclical Mastalgia based on the screening questionnaire (n=15) were found to have higher peak perimenstrual Mastalgia according to their daily diaries than patients who did not meet diagnostic criteria (n=15) (5.3±0.7 vs 3.5±0.5, P Conclusions Accurate assessment of Mastalgia cannot be done with a retrospective questionnaire and requires prospective diary evaluation, owing to the variable and subjective nature of symptoms and recall bias. A daily visual analog scale provides reproducible results and is easy for patients to use.
-
update on clinical and research issues in cyclical Mastalgia
Breast Journal, 1998Co-Authors: M Shahla D Masood, Deborah N Ader, D Ltc Craig M D ShriverAbstract:: The most common breast complaint presented to primary care and breast clinic providers is pain, and the majority of such pain is cyclical. Cyclical Mastalgia is poorly understood, inadequately assessed, and not systematically treated in the United States, although it is a recognized, and commonly treated disorder in Britain. Over 60% of premenopausal women regularly experience some premenstrual breast discomfort. Approximately 10--15% of these women have clinically significant Mastalgia each month, which can interfere with usual activities and is associated with elevated use of mammography among young women. The etiology of cyclical Mastalgia and its relationship to other disorders have not been established. Well-substantiated effective treatment options are somewhat limited, often associated with adverse effects, and rarely prescribed by physicians in the United States. This article reviews the literature on the prevalence, impact, etiology, assessment, relationship to other disorders, and treatment of cyclical Mastalgia, including recent findings from research in our Obstetrics and Gynecology clinic and Comprehensive Breast Care Center. Approaches to assessment and management are suggested, as are directions for further research. We suggest that understanding and effective management of cyclical Mastalgia will be fostered by a systematic biopsychosocial, interdisciplinary approach to research.
-
cyclical Mastalgia prevalence and impact in an outpatient breast clinic sample
Journal of The American College of Surgeons, 1997Co-Authors: Deborah N Ader, Craig D ShriverAbstract:Abstract Background: A descriptive study was conducted to examine prevalence of premenstrual breast symptoms, impact of cyclical Mastalgia on various activities, and associated patterns of health care utilization among breast clinic outpatients. Study Design: Patients (n = 231, age Results: Seventy-nine percent reported having regularly experienced cyclical breast symptoms; 48% have asked a health care provider about their Mastalgia. Young women (≤ 35 years) were more than three times as likely to have had a mammogram (75%) if they regularly experienced cyclical Mastalgia than if they did not (24%; p Conclusions: Reported prevalences of Mastalgia obtained in this sample are higher than those reported in British studies; possible reasons for these differences are discussed. Cyclical Mastalgia is a common problem sometimes severe enough to interfere with normal activity levels, and it is related to excessive use of mammography among young women. Although largely ignored both scientifically and clinically in the United States, this condition merits further biopsychosocial investigation.
-
prevalence and impact of cyclic Mastalgia in a united states clinic based sample
American Journal of Obstetrics and Gynecology, 1997Co-Authors: Deborah N Ader, Matrice W BrowneAbstract:Abstract OBJECTIVES: A descriptive study was conducted to examine the prevalence of premenstrual breast symptoms, the impact of cyclic Mastalgia on various activities, and associated patterns of health care utilization. STUDY DESIGN: Patients at an obstetrics and gynecology clinic ( n = 1171) completed a questionnaire. RESULTS: Sixty-nine percent of women reported regular premenstrual discomfort; 36% had consulted a health care provider about the symptoms. Current moderate-to-severe cyclic Mastalgia was found in 11%. Women CONCLUSIONS: Cyclic Mastalgia is a common problem, sometimes severe enough to interfere with usual activities, and it is associated with high use of mammography among young women. Largely ignored both scientifically and clinically in the United States, this disorder merits further biopsychosocial investigation. (Am J Obstet Gynecol 1997;177:126-32)
Genevieve Plubureau - One of the best experts on this subject based on the ideXlab platform.
-
cyclical Mastalgia and breast cancer risk results of a french cohort study
Cancer Epidemiology Biomarkers & Prevention, 2006Co-Authors: Genevieve Plubureau, Regine Sitrukware, Jeanchristophe ThalabardAbstract:Cyclical Mastalgia is a common complaint, with a potentially important relationship to breast cancer risk. In the last decade, case-control studies have reported that cyclical Mastalgia could be considered as an independent risk factor for breast cancer. The subjectivity of a retrospectively collected symptom questioned the validity of this finding. We have examined the association between cyclical Mastalgia and breast cancer risk in the French cohort study of women with benign breast disease diagnosed in two breast clinics between 1976 and 1979 and followed-up until 1997. The present study was restricted to the women free of any hormonal treatment (n = 247). The mean follow-up was 16 +/- 5 years, and a total of 22 breast cancers occurred during the follow-up. Using a Cox model with duration of cyclical Mastalgia as a time-varying variable, the adjusted relative risk of breast cancer increased with the duration of cyclical Mastalgia (P = 0.006). The corresponding relative risk for 37 months of cyclical Mastalgia was 5.31 (95% confidence interval, 1.92-14.72). We show here that the conclusion still holds when the symptom cyclical Mastalgia was collected prospectively in a cohort study, bringing additional evidence that cyclical Mastalgia may represent an independent and useful clinical marker of increased breast cancer risk. It might be a confounding factor when assessing the effects of hormonal treatments on breast cancer risk such as hormonal replacement therapy or oral contraceptives.
Juliawati Muhammad - One of the best experts on this subject based on the ideXlab platform.
-
a systematic review and meta analysis of the efficacy of evening primrose oil for Mastalgia treatment
International Journal of Environmental Research and Public Health, 2021Co-Authors: Lina Liana Ahmad Adni, Mohd Noor Norhayati, Ritzzaleena Rosli Mohd Rosli, Juliawati MuhammadAbstract:Mastalgia, or breast pain, is common among women which can lead to significant impairment in daily living. Hence, finding an effective treatment that can alleviate the symptom is very important. Thus, we carry out this study to determine the efficacy of evening primrose oil (EPO) for Mastalgia treatment in women. The review included published randomised clinical trials that evaluated EPO used for treating Mastalgia against a placebo or other treatments, irrespective of the blinding procedure, publication status, or sample size. Two independent authors screened the titles and abstracts of the identified trials; full texts of relevant trials were evaluated for eligibility. Two reviewers independently extracted data on the methods, interventions, outcomes, and risk of bias. The random-effects model was used for estimating the risk ratios and mean differences with 95% confidence intervals. Thirteen trials with 1752 randomised patients were included. The results showed that EPO has no difference to reduce breast pain compared to topical NSAIDS, danazol, or vitamin E. The number of patients who achieved pain relief was no different compared to the placebo or other treatments. The EPO does not increase adverse events, such as nausea, abdominal bloating, headache or giddiness, increase weight gain, and altered taste compared to a placebo or other treatments. EPO is a safe medication with similar efficacy for pain control in women with Mastalgia compared to a placebo, topical NSAIDS, danazol, or vitamin E.
Haixia Jia - One of the best experts on this subject based on the ideXlab platform.
-
a double blind randomized controlled trial of toremifen therapy for Mastalgia
Archives of Surgery, 2006Co-Authors: Chang Gong, Erwei Song, Weijuan Jia, Li Qin, Jujiang Guo, Haixia JiaAbstract:Hypothesis Toremifen is effective in reducing breast pain and does not increase the incidence of adverse events as a therapy for moderate to severe Mastalgia. Design and Patients In a double-blind randomized controlled trial, patients with moderate to severe Mastalgia received toremifen citrate, 30 mg daily, or a placebo tablet for 3 menstrual cycles and were followed up for breast pain score and adverse events. The serum levels of estradiol, progesterone, and prolactin were examined before treatment and correlated with the response rate to toremifen treatment. Results Seventy-two (69.2%) of 104 patients receiving toremifen and 29 (31.9%) of 91 receiving placebo responded to the treatment, with reduction in breast pain score of more than 50% ( P P P = .09). Adverse events were observed in 44 (42.9%) of 104 patients receiving placebo and 46 (50.5%) of 91 patients receiving toremifen ( P = .45). A positive correlation between baseline breast pain score and serum estradiol level was observed in patients with cyclical Mastalgia ( r = 0.35, P = .003). Conclusions Toremifen effectively relieves moderate and severe cyclical Mastalgia and tends to exert a positive therapeutic effect on noncyclical Mastalgia. In addition, toremifen therapy does not increase the incidence of intolerable adverse event. Therefore, it is a feasible therapy for Mastalgia, especially cyclical Mastalgia.